Indinavir
From Proteopedia
(Difference between revisions)
| Line 57: | Line 57: | ||
! Ritonavir | ! Ritonavir | ||
! Tipranavir | ! Tipranavir | ||
| - | ! | + | ! 65 |
! Saquinavir | ! Saquinavir | ||
! Amprenavir | ! Amprenavir | ||
| Line 68: | Line 68: | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%) | ! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%) | ||
| - | ! | + | ! 99 |
! Tipranavir | ! Tipranavir | ||
| - | ! | + | ! 61 |
! Saquinavir | ! Saquinavir | ||
! Amprenavir | ! Amprenavir | ||
| Line 81: | Line 81: | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
| - | ! | + | ! 4 |
! Tipranavir | ! Tipranavir | ||
| - | ! | + | ! 1.8 |
! Saquinavir | ! Saquinavir | ||
! Amprenavir | ! Amprenavir | ||
| Line 133: | Line 133: | ||
|- | |- | ||
! Metabolism | ! Metabolism | ||
| - | ! | + | ! Hepatic (CYP3A4) |
! Tipranavir | ! Tipranavir | ||
| - | ! | + | ! Hepatic (CYP3A4) |
! Saquinavir | ! Saquinavir | ||
! Amprenavir | ! Amprenavir | ||
Revision as of 19:11, 1 December 2010
|
Better Known as:
- Marketed By:
- Major Indication: Human Immunodeficiency Virus Infection
- Drug Class: HIV Protease Inhibitor
- Date of FDA Approval (Patent Expiration):
- 2006 Sales:
- Importance:
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| HIV Protease Inhibitor Pharmacokinetics | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Tmax (hr) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Cmax (ng/ml) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Bioavailability (%) | Ritonavir | Tipranavir | 65 | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Protein Binding (%) | 99 | Tipranavir | 61 | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| T1/2 (hr) | 4 | Tipranavir | 1.8 | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| AUC (ng/ml/hr) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| IC50 (nM) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Dosage (mg) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Metabolism | Hepatic (CYP3A4) | Tipranavir | Hepatic (CYP3A4) | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
References
